Navigation Links
Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
Date:12/17/2007

where in our public documents constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to advance the development of Celacade(TM) or VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factor
'/>"/>
SOURCE Vasogen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... MENLO PARK, Calif. , July 23, 2014 /PRNewswire/ ... based investment firm, today announced the closing of Sofinnova ... $500 million and in excess of the initial fund ... on helping entrepreneurs build successful biotechnology companies. Consistent with ... companies with promising later stage clinical programs, along with ...
(Date:7/23/2014)... MD (PRWEB) July 23, 2014 a2z ... and ChirpE Mobile App, AACC Pathfinder, in its ... offerings. AACC’s annual meeting is planned for July 29-31, ... the place to be to connect with global leaders ... lab management, and other areas of breaking science in ...
(Date:7/22/2014)... 2014 The Board of Directors of BD (Becton, ... a quarterly dividend of 54.5 cents per common share payable ... 9, 2014. The indicated annual dividend rate is $2.18 per ... a leading medical technology company that partners with customers and ... evolving health needs. Our innovative solutions are focused on improving ...
(Date:7/22/2014)... Dr. Terry Baughn, a senior lecturer in mechanical engineering ... named Engineer of the Year by the North Texas ... , ASME has more than 130,000 members in 158 ... share technology to assist the engineering community, benefiting the ... the Texas Society of Professional Engineers honors banquet. Baughn ...
Breaking Biology Technology:Sofinnova Raises $500 Million Biotech Venture Fund 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3UT Dallas professor receives Engineer of the Year award 2
... insurance premiums have increased approximately 113% over the past ... by the Kaiser Family Foundation, the reverse is true ... demonstrably cheaper over the past 25 years, due primarily ... competitive market pressures. In addition, many new enhancements to ...
... March 1, 2012 The second phase of ... Healthy Weight," is being announced today by the ... partnership with the Health Resources and Services Administration ... community leaders, from Pasadena to Philadelphia, have been ...
... 2012  AtheroNova Inc. (OTCBB: AHRO), a biotech company focused ... atherosclerotic plaque, today announced that it has initiated the ... its research and development partner CardioNova, Ltd., a Russia ... human clinical studies of AHRO-001. The clinical-grade material will ...
Cached Biology Technology:WestPark Capital's Michael Wechsler Comments on the Life Insurance Market 2Groundbreaking National Program to Reverse Obesity Expands to 50 Locations 2AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001 2AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001 3
(Date:7/23/2014)... 2014 BioCatch, the global leader ... it has been named in Gartner,s Market Guide for ... Gartner,s well-known Magic Quadrant for Web Fraud Detection. ... of several vendors to deliver passive biometric analysis and ... standard feature of at least 30% of one-stop fraud ...
(Date:7/23/2014)... starfish, and corals have in common? Aside from ... that use calcium from their environment to create ... protection. , The July issue of The ... Laboratory, addresses the challenges faced by these species ... carbon dioxide rises, the world,s oceans are becoming ...
(Date:7/23/2014)... Streptococcus mutans , one of the principal bacteria ... in its genetic material over time, possibly coinciding ... humanity. This is highlighted in a study ... (UAB) and the Laboratorio Nacional de Genmica para ... in Mexico who, for the first time, have ...
Breaking Biology News(10 mins):BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3Calcification in changing oceans explored in special issue of The Biological Bulletin 2Ancient genetic material from caries bacterium obtained for the first time 2
... that snakes can optimize their vision by controlling the blood ... Kevin van Doorn, PhD, and Professor Jacob Sivak, from the ... blood flow patterns change depending on what,s in its environment. ... Journal of Experimental Biology . "Each species, perception ...
... If cats really had nine lives, one reason might be ... threaten feline health. Yunjeong Kim, a research assistant professor ... has developed a research approach that tackles two deadly infectious ... supported by a $156,342 award from the Morris Animal Foundation. ...
... Whitehead Institute scientists report that the gene mutated ... syndrome also prevents activation of mTORC1, a critical nutrient-sensing ... is an unexpected finding, as some cancers keep this ... expansion. In the case of Birt-Hogg-Dub syndrome, the mutated ...
Cached Biology News:Snakes control blood flow to aid vision 2College of Veterinary Medicine researcher doubles down on deadly, infectious cat diseases 2College of Veterinary Medicine researcher doubles down on deadly, infectious cat diseases 3Gene responsible for hereditary cancer syndrome found to disrupt critical growth-regulating pathway 2
Control primers and template for 5kb and 15 kb products....
Carrier Serum...
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: